Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising PipelineSeeking Alpha • 06/12/24
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaGlobeNewsWire • 06/03/24
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024GlobeNewsWire • 05/30/24
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break OutInvestors Business Daily • 05/28/24
How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%Zacks Investment Research • 05/24/24
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressGlobeNewsWire • 05/14/24
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?Zacks Investment Research • 05/08/24
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024GlobeNewsWire • 05/03/24
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024GlobeNewsWire • 04/18/24
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024GlobeNewsWire • 03/05/24
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024GlobeNewsWire • 02/22/24
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/15/24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/15/24
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to DeclineZacks Investment Research • 02/08/24
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024GlobeNewsWire • 02/02/24